Jun. 22, 2015
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products announced on June 22, 2015 that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology.
3SBio previously acquired the China rights from Apexigen in 2006. 3SBio's anti-TNF mAb, designated SSS07, has completed pre-clinical testing and demonstrated higher potency than the best-known available TNF inhibitors, including adalimumab and infliximab, potentially improving treatment options for patients with rheumatoid arthritis and other inflammatory diseases.
In March 2015, 3SBio initiated a dose-escalating Phase I trial for SSS07 in China (NCT02460393). A Phase 1b trial is also scheduled to start in early 2016 using multiple doses in healthy individuals.